Skip to main content
SpringerLink
Log in

Inhibitor questions: plasma-derived factor VIII and recombinant factor VIII

  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Davidson CS, Epstein RD, Miller GF, Taylor FHL (1949) Hemophilia. A clinical study of forty patients. Blood 4: 97–119

    Google Scholar 

  2. Strauss HS (1969) Acquired circulating anticoagulants in hemophilia A. N Engl J Med 281:866–873

    PubMed  Google Scholar 

  3. Biggs R (1974) Jaundice and antibodies directed against factors VIII and IX in patients treated for haemophilia or Christmas disease in the United Kingdom. Br J Haematol 26: 313–329

    PubMed  Google Scholar 

  4. Brinkhous KM, Roberts HR, Weiss AE (1972) Prevalence of inhibitors in hemophilia A and B. Thromb Diath Haemorrh [Suppl 51]:315–321

    Google Scholar 

  5. Gill F (1984) The natural history of factor VIII inhibitors in patients with hemophilia A. Prog Clin Biol Res 150: 19–29

    PubMed  Google Scholar 

  6. Schwarzinger I, Papinger I, Korninger C et al. (1987) Incidence of inhibitors in patients with severe and moderate hemophilia A treated with factor VIII concentrates. Am J Hematol 24:241–245

    PubMed  Google Scholar 

  7. Rasi V, Ikkala E (1990) Haemophiliacs with factor VIII inhibitors in Finland: prevalence, incidence and outcome. Br J Haematol 76:369–371

    PubMed  Google Scholar 

  8. Ehrenforth S, Kreuz W, Scharrer I et al. (1992) Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 339:594–598

    PubMed  Google Scholar 

  9. Addiego J, Kasper C, Abildgaard C et al. (1992) Inhibitors in factor VIII deficient hemophilia: comparison of frequency based upon treatment product. Blood80 [Suppl 1]:913a

    Google Scholar 

  10. Lusher JM (1991) Viral safety and inhibitor development associated with monoclonal antibody-purified FVIIIC. Ann Hematol 63:138–141

    PubMed  Google Scholar 

  11. Addiego JE, Gomperts E, Liu S-L (1992) Treatment of hemophilia A with a highly purified factor VIII concentrate prepared by anti-FVIII:C immunoaffinity chromatography. Thromb Haemostas 67:19–27

    Google Scholar 

  12. Peerlinck K, Arnout J, Gilles JG et al. (1993) A higher than expected incidence of factor VIII inhibitors in multitransfused haemophilia A patients treated with an intermediate purity pasteurized factor VIII concentrate. Thromb Haemostas 69: 115–118

    Google Scholar 

  13. Kaufman RJ (1991): Insight into the structure, function and biosynthesis of factor VIII through recombinant DNA technology. Ann Hematol 63:155–165

    PubMed  Google Scholar 

  14. Bray GL (1992) Current status of clinical studies of recombinant factor VIII (Recombinate) in patients with hemophilia A. Trans Med Rev 6:252–255

    Google Scholar 

  15. Schwartz R, Abildgaard CF, Aledort LM et al. (1990) Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A. N Engl J Med 323:1800–1805

    PubMed  Google Scholar 

  16. Scandella D, Bray GL, Liu-Maruya S et al. (1992) Epitope specificity of anti-factor VIII antibodies in hemophilia A patients treated with recombinant factor VIII. Blood 80 [Suppl 1]: 1456a

    Google Scholar 

  17. Lusher JM, Arkin S, Abildgaard CF et al. (1993) Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. N Engl J Med 328:453–459

    PubMed  Google Scholar 

  18. Bray GL, Liu-Maruya S, Courter S et al. (1992) Two years' experience with recombinant factor VIII (Recombinate) in previously untreated patients with hemophilia A. Blood 80 [Suppl 1]:908a

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hyland Division, Baxter Biotech., 550 N. Brand Blvd., Glendale, CA, USA

    G. Bray (Clinical Development Director)

Authors
  1. G. Bray
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bray, G. Inhibitor questions: plasma-derived factor VIII and recombinant factor VIII. Ann Hematol 68 (Suppl 3), S29–S34 (1994). https://doi.org/10.1007/BF01774527

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01774527

Keywords

Search

Navigation